Top

Supportive Care in Cancer

Published in:

01-10-2014 | Original Article

Evaluation of the Semmes–Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy

Authors: Delma Aurélia da Silva Simão, Antônio Lúcio Teixeira, Raissa Silva Souza, Elenice Dias Ribeiro de Paula Lima

Published in: Supportive Care in Cancer | Issue 10/2014

Abstract

Objective

This study aims to assess the use of Semmes–Weinstein monofilaments (SWMs) and of the Chemotherapy-Induced Neurotoxicity Questionnaire (CINQ) in the detection of chemotherapy-induced peripheral neuropathy (CIPN).

Method

It is a comparative and cross-sectional study performed in a philanthropic general hospital, located in the state of Minas Gerais, Brazil. One hundred seventeen individuals have participated in this study; they were divided into two groups: patients (n = 87) treated with oxaliplatin, paclitaxel, or docetaxel and controls (n = 30) without malignant disease.

Results

There were statistically significant differences between groups for all symptoms assessed by means of the CINQ. Lower limbs were more severely affected. Patients had increased frequency and severity of changes in all points assessed with SWM compared with controls. In the analyses of concordance between CINQ and SWM, kappa = 0.320 (p < 0.001) was obtained, and there was a moderate and positive correlation (ρ = 0.357; p < 0.001).

Conclusion

CINQ and SWM may be valid tools for diagnosing CIPN in oncology practice. SWM may identify subclinical CIPN.

Marrs J, Newton S (2010) Updating your peripheral neuropathy “know-how”. Clin J Oncol Nurs 7(3):299–303CrossRef

Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323–331PubMedCrossRef

Winer EP, Berry DA, Woolf S et al (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial. J Clin Oncol 22:2061–2068PubMedCrossRef

Visovisky C, Collins M, Abbot L, Aschenbrenner J, Hart C (2007) Evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 11(6):911–913CrossRef

Kwak MK, Kim ER, Kwon I, Hwang MS (2010) Characteristics and quality of life in pacients with chemotherapy-induced peripheral neuropathy. J Korean Oncol Nurs 10(2):231–239CrossRef

Wilson R, Lehky T, Thommas RR, Quinn MG, Floetter MK, Grem JL (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20(7):1767–1774PubMedCrossRef

Smith EML, Beck SL, Cohen J (2008) The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 35(1):96–102PubMedCrossRef

Visovisky C, Meyer RR, Roller J, Poppas M (2008) Evaluation and management of peripheral neuropathy in diabetic patients with cancer. Clin J Oncol Nurs 12(2):243–247CrossRef

Wickham R (2007) Chemotherapy-induced peripheral neuropathy: a review and implication for oncology nursing practice. Clin J Oncol Nurs 11(3):361–376PubMedCrossRef

10.

Binner M, Ross D, Browner I (2011) Chemotherapy-induced peripheral neuropathy: assessment of oncology nurses’ knowledge and practice. Oncol Nurs Forum 38(4):448–454PubMedCrossRef

11.

Garbino JA (1998) Abordagem clínica e eletrofisiológica em neuropatias periféricas. Acta Fisiatrica 5(1):11–17

12.

Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, Zara G et al (2007) The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 12(3):210–215PubMedCrossRef

13.

National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). 2009. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40>

14.

Simao DAS, Lima ERP, Souza RS, Alves KR, Maia WM (2012) Instrumentos de avaliação da neuropatia periférica induzida por quimioterapia—revisão integrativa e implicações para a prática de enfermagem oncológica. Rev Min Enferm 16(4):601–608

15.

Cella D, Peterman A, Hudgens S, Webster K, Socinski MA (2003) Measuring the side effect of taxane therapy in oncology. Cancer 98:822–831PubMedCrossRef

16.

Huang HQ, Brady MF, Cella D, Fleming G (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17(2):387–393PubMedCrossRef

17.

Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lantéri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R, EORTC Quality of Life Group (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139PubMedCrossRef

18.

Leonard GD, Wright MA, Quinn MG et al (2005) Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 5:116–125PubMedCentralPubMedCrossRef

19.

Smith EM, Cohen JA, Pett MA, Beck SL (2010) The reliability and validity of a modified Total Neuropathy Score—reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in pacients receiving taxanes and platinums. Cancer Nurs 33(3):173–183PubMedCrossRef

20.

Shimozuma K, Ohashi Y, Takeuchi A, Aranish T, Morita S, Kuroi K et al (2009) Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17(12):1483–1491PubMedCrossRef

21.

Tofthagen CS, McMillan SC, Kip KE (2011) Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs 34(4):10–20CrossRef

22.

Lavoie Smith EM, Cohen JA, Pett MA, Beck SL (2011) The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums. Oncol Nurs Forum 38(2):133–142PubMedCrossRef

23.

Kautio AL, Haanpää M, Kautiainen H, Leminen A, Kalso E, Saarto T (2011) Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy. Anticancer Res 31(10):3493–3496PubMed

24.

Driessen CM, de Kleine-Bolt KM, Vingerhoets AJ, Mols F, Vreugdenhil G (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20:877–881PubMedCentralPubMedCrossRef

25.

Neumann CR, Schimid H. Polineuropatia do (1999) Diabetes Mellitus—Caracterização clínica e padronização dos testes autonômicos e Somáticos. [tese de doutorado]. Porto Alegre (RS): Faculdade de Medicina da Universidade Federal do Rio Grande do Sul. 171p

26.

Bell-Krotoski JA (1984) Semmes-Weistein monofilament testing for determining cutaneous light touch/deep pressure sensation. Star 44(2):8–11

27.

Cavaletti GDR, Cornblath ISJ, Merkies TJ, Postma E, Rossi B, Frigeni B et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24(2):454–462PubMedCentralPubMedCrossRef

28.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655PubMedCrossRef

29.

Ministério da Saúde (BR). Manual de prevenção de incapacidades. Brasília (DF): Secretaria de Vigilância em Saúde; Ministério da Saúde; 2008. 140 p

30.

Lehman LF, Orsini MB, Nicholl AR (1993) The development and adaptation of the Semmes Weinstein monofilaments in Brazil. J Hand Ther 6(4):290–297PubMedCrossRef

31.

Velasco R, Bruna J (2010) Chemotherapy-induced peripheral neuropathy: an unresolved issue. Neurologia 25(2):116–131PubMedCrossRef

32.

Yadav N, Philip FA, Gogia V, Choudhary P, Rana SP et al (2010) Radio frequency ablation in drug resistant chemotherapy-induced peripheral neuropathy: a case report and review of literature. Indian J Palliat Care 16:48–51PubMedCentralPubMedCrossRef

33.

Visovsky C, Daly BJ (2004) Clinical evaluation and patterns of chemotherapy-induced peripheral neuropathy. J Am Acad Nurse Pract 16(8):353–359PubMedCrossRef

34.

Bell-Krotoski JA (1991) Advances in sensibility evaluation. Hand Clin 7(3):527–546PubMed

Title: Evaluation of the Semmes–Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy
Authors: Delma Aurélia da Silva Simão
Antônio Lúcio Teixeira
Raissa Silva Souza
Elenice Dias Ribeiro de Paula Lima
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 10/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2275-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2014

The EAPC framework on palliative sedation and clinical practice—a questionnaire-based survey in Germany

Mandatory communication skills training for oncologists: enforcement does not substantially impact satisfaction

Characteristics and outcomes of advanced cancer patients who miss outpatient supportive care consult appointments

A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring — supporting patients in their homes

A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey

Holistic needs assessment in advanced, intensively treated multiple myeloma patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer